Tumor budding and human chorionic gonadotropin-β expression correlate with unfavorable patient outcome in colorectal carcinoma

Yuji Konishi, Futoshi Kawamata, Hiroshi Nishihara, Shigenori Homma, Yasutaka Kato, Masumi Tsuda, Shinji Kohsaka, Takahiro Einama, Cheng Liu, Tadashi Yoshida, Akihisa Nagatsu, Mishie Tanino, Shinya Tanaka, Hideki Kawamura, Toshiya Kamiyama, Akinobu Taketomi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Tumor budding is thought to represent a manifestation of epithelial-to-mesenchymal transition (EMT) and it has been correlated with poor patient outcomes in colorectal cancer (CRC). Our group recently demonstrated that human chorionic gonadotropin-β (hCGβ) modulates EMT in CRC. In the current study, based on the likely relationships between tumor budding and hCGβ expression, we examined their clinicopathologic significance in CRC. Twenty-eight of 80 (35.0%) CRC showed tumor budding. Tumor budding significantly correlated with lymph node metastasis (P < 0.01), pathologic stage (P < 0.01), lymphatic invasion (P = 0.044), and vascular invasion (P = 0.013). Thirteen of 80 (16.3%) CRC were hCGβ positive on immunohistochemistry. More tumor buds were present in the hCGβ-positive cases (P < 0.01), and tumor budding was significantly correlated with hCGβ positivity (P < 0.01). Cases with both tumor budding and hCGβ expression had the poorest prognosis compared with all other groups (P < 0.01). In conclusion, tumor budding and hCGβ expression are closely associated with EMT, and they are independent prognostic factors in CRC. They identify patients with an “EMT phenotype” who may respond to targeted molecular therapies.

Original languageEnglish
Article number104
JournalMedical Oncology
Volume35
Issue number7
DOIs
Publication statusPublished - 2018 Jul 1

Fingerprint

Chorionic Gonadotropin
Colorectal Neoplasms
Epithelial-Mesenchymal Transition
Neoplasms
Molecular Targeted Therapy
Blood Vessels
Lymph Nodes
Immunohistochemistry
Neoplasm Metastasis
Phenotype

Keywords

  • Colorectal cancer
  • Epithelial-to-mesenchymal transition
  • Human chorionic gonadotropin
  • Prognostic factor
  • Tumor budding

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Tumor budding and human chorionic gonadotropin-β expression correlate with unfavorable patient outcome in colorectal carcinoma. / Konishi, Yuji; Kawamata, Futoshi; Nishihara, Hiroshi; Homma, Shigenori; Kato, Yasutaka; Tsuda, Masumi; Kohsaka, Shinji; Einama, Takahiro; Liu, Cheng; Yoshida, Tadashi; Nagatsu, Akihisa; Tanino, Mishie; Tanaka, Shinya; Kawamura, Hideki; Kamiyama, Toshiya; Taketomi, Akinobu.

In: Medical Oncology, Vol. 35, No. 7, 104, 01.07.2018.

Research output: Contribution to journalArticle

Konishi, Y, Kawamata, F, Nishihara, H, Homma, S, Kato, Y, Tsuda, M, Kohsaka, S, Einama, T, Liu, C, Yoshida, T, Nagatsu, A, Tanino, M, Tanaka, S, Kawamura, H, Kamiyama, T & Taketomi, A 2018, 'Tumor budding and human chorionic gonadotropin-β expression correlate with unfavorable patient outcome in colorectal carcinoma', Medical Oncology, vol. 35, no. 7, 104. https://doi.org/10.1007/s12032-018-1164-x
Konishi, Yuji ; Kawamata, Futoshi ; Nishihara, Hiroshi ; Homma, Shigenori ; Kato, Yasutaka ; Tsuda, Masumi ; Kohsaka, Shinji ; Einama, Takahiro ; Liu, Cheng ; Yoshida, Tadashi ; Nagatsu, Akihisa ; Tanino, Mishie ; Tanaka, Shinya ; Kawamura, Hideki ; Kamiyama, Toshiya ; Taketomi, Akinobu. / Tumor budding and human chorionic gonadotropin-β expression correlate with unfavorable patient outcome in colorectal carcinoma. In: Medical Oncology. 2018 ; Vol. 35, No. 7.
@article{a7e3ccafb12745e2a7dd4914c708a6b5,
title = "Tumor budding and human chorionic gonadotropin-β expression correlate with unfavorable patient outcome in colorectal carcinoma",
abstract = "Tumor budding is thought to represent a manifestation of epithelial-to-mesenchymal transition (EMT) and it has been correlated with poor patient outcomes in colorectal cancer (CRC). Our group recently demonstrated that human chorionic gonadotropin-β (hCGβ) modulates EMT in CRC. In the current study, based on the likely relationships between tumor budding and hCGβ expression, we examined their clinicopathologic significance in CRC. Twenty-eight of 80 (35.0{\%}) CRC showed tumor budding. Tumor budding significantly correlated with lymph node metastasis (P < 0.01), pathologic stage (P < 0.01), lymphatic invasion (P = 0.044), and vascular invasion (P = 0.013). Thirteen of 80 (16.3{\%}) CRC were hCGβ positive on immunohistochemistry. More tumor buds were present in the hCGβ-positive cases (P < 0.01), and tumor budding was significantly correlated with hCGβ positivity (P < 0.01). Cases with both tumor budding and hCGβ expression had the poorest prognosis compared with all other groups (P < 0.01). In conclusion, tumor budding and hCGβ expression are closely associated with EMT, and they are independent prognostic factors in CRC. They identify patients with an “EMT phenotype” who may respond to targeted molecular therapies.",
keywords = "Colorectal cancer, Epithelial-to-mesenchymal transition, Human chorionic gonadotropin, Prognostic factor, Tumor budding",
author = "Yuji Konishi and Futoshi Kawamata and Hiroshi Nishihara and Shigenori Homma and Yasutaka Kato and Masumi Tsuda and Shinji Kohsaka and Takahiro Einama and Cheng Liu and Tadashi Yoshida and Akihisa Nagatsu and Mishie Tanino and Shinya Tanaka and Hideki Kawamura and Toshiya Kamiyama and Akinobu Taketomi",
year = "2018",
month = "7",
day = "1",
doi = "10.1007/s12032-018-1164-x",
language = "English",
volume = "35",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "7",

}

TY - JOUR

T1 - Tumor budding and human chorionic gonadotropin-β expression correlate with unfavorable patient outcome in colorectal carcinoma

AU - Konishi, Yuji

AU - Kawamata, Futoshi

AU - Nishihara, Hiroshi

AU - Homma, Shigenori

AU - Kato, Yasutaka

AU - Tsuda, Masumi

AU - Kohsaka, Shinji

AU - Einama, Takahiro

AU - Liu, Cheng

AU - Yoshida, Tadashi

AU - Nagatsu, Akihisa

AU - Tanino, Mishie

AU - Tanaka, Shinya

AU - Kawamura, Hideki

AU - Kamiyama, Toshiya

AU - Taketomi, Akinobu

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Tumor budding is thought to represent a manifestation of epithelial-to-mesenchymal transition (EMT) and it has been correlated with poor patient outcomes in colorectal cancer (CRC). Our group recently demonstrated that human chorionic gonadotropin-β (hCGβ) modulates EMT in CRC. In the current study, based on the likely relationships between tumor budding and hCGβ expression, we examined their clinicopathologic significance in CRC. Twenty-eight of 80 (35.0%) CRC showed tumor budding. Tumor budding significantly correlated with lymph node metastasis (P < 0.01), pathologic stage (P < 0.01), lymphatic invasion (P = 0.044), and vascular invasion (P = 0.013). Thirteen of 80 (16.3%) CRC were hCGβ positive on immunohistochemistry. More tumor buds were present in the hCGβ-positive cases (P < 0.01), and tumor budding was significantly correlated with hCGβ positivity (P < 0.01). Cases with both tumor budding and hCGβ expression had the poorest prognosis compared with all other groups (P < 0.01). In conclusion, tumor budding and hCGβ expression are closely associated with EMT, and they are independent prognostic factors in CRC. They identify patients with an “EMT phenotype” who may respond to targeted molecular therapies.

AB - Tumor budding is thought to represent a manifestation of epithelial-to-mesenchymal transition (EMT) and it has been correlated with poor patient outcomes in colorectal cancer (CRC). Our group recently demonstrated that human chorionic gonadotropin-β (hCGβ) modulates EMT in CRC. In the current study, based on the likely relationships between tumor budding and hCGβ expression, we examined their clinicopathologic significance in CRC. Twenty-eight of 80 (35.0%) CRC showed tumor budding. Tumor budding significantly correlated with lymph node metastasis (P < 0.01), pathologic stage (P < 0.01), lymphatic invasion (P = 0.044), and vascular invasion (P = 0.013). Thirteen of 80 (16.3%) CRC were hCGβ positive on immunohistochemistry. More tumor buds were present in the hCGβ-positive cases (P < 0.01), and tumor budding was significantly correlated with hCGβ positivity (P < 0.01). Cases with both tumor budding and hCGβ expression had the poorest prognosis compared with all other groups (P < 0.01). In conclusion, tumor budding and hCGβ expression are closely associated with EMT, and they are independent prognostic factors in CRC. They identify patients with an “EMT phenotype” who may respond to targeted molecular therapies.

KW - Colorectal cancer

KW - Epithelial-to-mesenchymal transition

KW - Human chorionic gonadotropin

KW - Prognostic factor

KW - Tumor budding

UR - http://www.scopus.com/inward/record.url?scp=85048462349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048462349&partnerID=8YFLogxK

U2 - 10.1007/s12032-018-1164-x

DO - 10.1007/s12032-018-1164-x

M3 - Article

C2 - 29892782

AN - SCOPUS:85048462349

VL - 35

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 7

M1 - 104

ER -